Mostrar el registro sencillo del ítem
| dc.contributor.author | Oreja-Guevara, Celia | |
| dc.contributor.author | Gómez-Estevez, Irene | |
| dc.contributor.author | Aguado-García, Laura | |
| dc.contributor.author | Martin-Martínez, Jesus | |
| dc.contributor.author | Gómez-Gutiérrez, Montserrat | |
| dc.contributor.author | Gascon-Gimenez, Francisco | |
| dc.contributor.author | Aguera-Morales, Eduardo | |
| dc.contributor.author | Meca-Lallana, Virginia | |
| dc.contributor.author | Barrero-Hernández, Francisco-Javier | |
| dc.contributor.author | González-Quintanilla, Vicente | |
| dc.contributor.author | Romero-Pinel, Lucía | |
| dc.contributor.author | Delgado-Gil, Virginia | |
| dc.contributor.author | Duran-Ferreras, Eduardo | |
| dc.contributor.author | Blasco-Quilez, Rosario | |
| dc.contributor.author | Meca-Lallana, José-Eustasio | |
| dc.contributor.author | Landete-Pascual, Lamberto | |
| dc.contributor.author | Aladro-Benito, Yolanda | |
| dc.contributor.author | Boyero-Duran, Sabas | |
| dc.contributor.author | Gracia-Gil, Julia | |
| dc.contributor.author | Caminero-Rodríguez, Ana-Belén | |
| dc.contributor.author | Cano-Orgaz, Antonio-Tomas | |
| dc.contributor.author | Eichau-Madueno, Sara | |
| dc.contributor.author | Querol-Pascual, María-Rosa | |
| dc.contributor.author | Otano-Martínez, María | |
| dc.contributor.author | Alonso-Torres, Ana-María | |
| dc.contributor.author | Calles-Hernández, Carmen | |
| dc.contributor.author | López-Real, Ana | |
| dc.contributor.author | Ares-Luque, Adrian | |
| dc.contributor.author | Lorenzo-González, José-Ramón | |
| dc.contributor.author | Gómez-Vicente, Lidia | |
| dc.contributor.author | Diaz-Sánchez, María | |
| dc.date.accessioned | 2026-10-28T08:18:17Z | |
| dc.date.available | 2026-10-28T08:18:17Z | |
| dc.date.issued | 2026-08 | |
| dc.identifier.citation | Oreja-Guevara C, Gómez-Estévez I, Agüado García L, Martín Martínez J, Gómez Gutiérrez M, Gascón Giménez F, et al. Real-world siponimod use in secondary progressive multiple sclerosis: the RESYZE study. Ther Adv Neurol Disord. agosto de 2026;19:17562864261472650. doi:10.1177/17562864261472650 | |
| dc.identifier.issn | 1756-2856 | |
| dc.identifier.uri | https://sms.carm.es/ricsmur/handle/123456789/29064 | |
| dc.language.iso | eng | |
| dc.publisher | SAGE PUBLICATIONS LTD | |
| dc.rights | Atribución/Reconocimiento-NoComercial 4.0 Internacional | |
| dc.rights.uri | https://creativecommons.org/licenses/by-nc/4.0/deed.es | * |
| dc.title | Real-world siponimod use in secondary progressive multiple sclerosis: the RESYZE study | |
| dc.type | info:eu-repo/semantics/article | |
| dc.relation.publisherversion | https://journals.sagepub.com/doi/10.1177/17562864261472650 | |
| dc.type.version | info:eu-repo/semantics/publishedVersion | |
| dc.identifier.doi | 10.1177/17562864261472650 | |
| dc.journal.title | Therapeutic Advances in Neurological Disorders | |
| dc.identifier.essn | 1756-2864 |